[go: up one dir, main page]

AR066987A1 - Anticuerpo monoclonal contra proteina beta-amiloide - Google Patents

Anticuerpo monoclonal contra proteina beta-amiloide

Info

Publication number
AR066987A1
AR066987A1 ARP080102521A ARP080102521A AR066987A1 AR 066987 A1 AR066987 A1 AR 066987A1 AR P080102521 A ARP080102521 A AR P080102521A AR P080102521 A ARP080102521 A AR P080102521A AR 066987 A1 AR066987 A1 AR 066987A1
Authority
AR
Argentina
Prior art keywords
amyloid
peptides
monoclonal antibody
protein
amylide
Prior art date
Application number
ARP080102521A
Other languages
English (en)
Original Assignee
Ac Immune Sa
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa, Genentech Inc filed Critical Ac Immune Sa
Publication of AR066987A1 publication Critical patent/AR066987A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)

Abstract

Métodos y composiciones que comprenden los anticuerpos para el uso terapéutico y de diagnostico para el tratamiento de enfermedades y trastornos causados o relacionados con las proteínas amiloides o similares que incluye a la amiloidosis, un grupo de trastornos y anormalidades relacionadas con la proteína amiloide tal como la enfermedad de Alzheirner. Reivindicacion 1: Un anticuerpo monoclonal que incluye cualquier anticuerpo funcionalmente equivalente o sus partes funcionales, que reconoce un epítope conformacional y se une a péptidos amiloides solubles poliméricos y péptidos amiloides oligoméricos, respectivamente, particularmente a los péptidos Abeta amiloides solubles poliméricos y a los péptidos Abeta amiloides oligoméricos que comprenden una pluralidad de péptidos Abeta1-42 monoméricos, respectivamente.
ARP080102521A 2007-06-12 2008-06-12 Anticuerpo monoclonal contra proteina beta-amiloide AR066987A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94354307P 2007-06-12 2007-06-12
US94354107P 2007-06-12 2007-06-12
US94379007P 2007-06-13 2007-06-13

Publications (1)

Publication Number Publication Date
AR066987A1 true AR066987A1 (es) 2009-09-23

Family

ID=39790376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102521A AR066987A1 (es) 2007-06-12 2008-06-12 Anticuerpo monoclonal contra proteina beta-amiloide

Country Status (18)

Country Link
EP (2) EP2170953B1 (es)
JP (2) JP5436414B2 (es)
KR (2) KR20160017126A (es)
CN (1) CN101802007B (es)
AR (1) AR066987A1 (es)
AU (1) AU2008267037B2 (es)
BR (1) BRPI0812484A2 (es)
CA (1) CA2690434C (es)
CL (3) CL2008001742A1 (es)
ES (1) ES2548102T3 (es)
IL (1) IL202563A (es)
MX (1) MX2009013503A (es)
NZ (2) NZ581835A (es)
PE (2) PE20131141A1 (es)
RU (1) RU2571856C2 (es)
TW (2) TWI516500B (es)
WO (1) WO2008156621A1 (es)
ZA (1) ZA201000049B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20070040824A (ko) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
MX2009013503A (es) * 2007-06-12 2010-01-27 Genentech Inc Anticuerpo monoclonal anti-amiloide-beta.
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
JP5991535B2 (ja) 2011-02-18 2016-09-14 国立大学法人東京農工大学 アミロイドタンパク質オリゴマー結合アプタマー
CN102921007B (zh) * 2011-08-09 2014-12-10 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
KR102031317B1 (ko) 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
IL242088B2 (en) 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
CN109415431A (zh) * 2016-04-20 2019-03-01 爱兰细胞技术公司 与k180二甲基化h1.0蛋白相关的组合物和方法
CN116333108A (zh) 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN112912732A (zh) * 2018-08-03 2021-06-04 香港大学 用于淀粉样蛋白原纤维、淀粉样蛋白斑块、rna和核仁的检测和成像的组合物和方法
KR101977410B1 (ko) * 2018-08-22 2019-05-10 주식회사 피플바이오 당뇨병에 대한 신규 바이오마커 및 그의 용도
EP3877399A4 (en) 2018-11-06 2022-10-19 Alsatech, Inc. CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
CN111518205B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP3757125A1 (en) * 2019-06-28 2020-12-30 BioArctic AB Antibody directed against the apoe amino-terminal fragment of 12 kda
CN110317814A (zh) * 2019-07-19 2019-10-11 莫丁丁 β-淀粉样蛋白环状核糖核酸、多肽及其应用
MX2022002873A (es) * 2019-09-10 2022-03-25 Ac Immune Sa Nuevas moleculas para diagnostico.
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN110687035A (zh) * 2019-10-10 2020-01-14 沈阳万类生物科技有限公司 Annexin V-Light 650凋亡检测试剂盒
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
CN113308439B (zh) * 2020-11-06 2023-05-05 华中科技大学 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
CN113057963B (zh) * 2021-03-31 2022-05-20 华中科技大学 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
KR102565470B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물
KR102565471B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN119390832A (zh) * 2024-10-12 2025-02-07 中国科学技术大学 一种兔源Aβ 1-40单克隆抗体、制备方法及应用
CN120098147B (zh) * 2025-05-07 2025-07-15 中山大学 一种纳米自组装抗Aβ抗体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
ZA938243B (en) * 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
CA2127476C (en) 1994-07-06 1999-12-07 Daniel G. Pomerleau Logging or measurement while tripping
US7129337B1 (en) 1994-10-21 2006-10-31 Innogenetics N.V. Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
DE852011T1 (de) * 1995-09-14 2001-10-11 Scripps Res Inst La Jolla Für natives prp-sc spezifische antikörper
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
NZ524523A (en) 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2003014162A1 (en) * 2001-08-03 2003-02-20 Medical & Biological Laboratories Co., Ltd. ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
WO2003039467A2 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid.
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7220833B2 (en) 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
MXPA05006940A (es) 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2004065569A2 (en) * 2003-01-23 2004-08-05 The Regents Of The University Of California Multi-functional antibodies
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
KR20070040824A (ko) * 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
CA2607868A1 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
JP2009505640A (ja) * 2005-08-11 2009-02-12 − ロジャーズ、アルピ マトシアン 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
MX2009013503A (es) * 2007-06-12 2010-01-27 Genentech Inc Anticuerpo monoclonal anti-amiloide-beta.

Also Published As

Publication number Publication date
JP2014087353A (ja) 2014-05-15
CL2008001742A1 (es) 2008-11-21
JP2010530227A (ja) 2010-09-09
ES2548102T3 (es) 2015-10-13
AU2008267037B2 (en) 2014-08-07
TWI516500B (zh) 2016-01-11
NZ601843A (en) 2014-01-31
CN101802007B (zh) 2017-08-25
TW200906852A (en) 2009-02-16
AU2008267037A1 (en) 2008-12-24
IL202563A (en) 2016-05-31
RU2010100354A (ru) 2011-07-20
KR20160017126A (ko) 2016-02-15
BRPI0812484A2 (pt) 2018-06-05
EP2170953B1 (en) 2015-07-15
PE20131141A1 (es) 2013-10-14
CN101802007A (zh) 2010-08-11
PE20090831A1 (es) 2009-07-10
EP2527366A1 (en) 2012-11-28
KR101600095B1 (ko) 2016-03-07
JP5436414B2 (ja) 2014-03-05
MX2009013503A (es) 2010-01-27
TWI453217B (zh) 2014-09-21
RU2571856C2 (ru) 2015-12-20
IL202563A0 (en) 2011-08-01
CA2690434A1 (en) 2008-12-24
ZA201000049B (en) 2018-11-28
TW201441256A (zh) 2014-11-01
EP2527366B1 (en) 2017-08-16
NZ581835A (en) 2012-09-28
HK1140500A1 (en) 2010-10-15
CA2690434C (en) 2018-05-22
CL2012001817A1 (es) 2012-12-14
EP2170953A1 (en) 2010-04-07
CL2012000631A1 (es) 2012-10-05
KR20100027216A (ko) 2010-03-10
WO2008156621A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
AR066987A1 (es) Anticuerpo monoclonal contra proteina beta-amiloide
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
CR20150016A (es) Anticuerpo monoclonal
ECSP13012609A (es) Composición farmacéutica
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CY1115906T1 (el) Ανθρωποποιημενα αντισωματα κατα του βητα αμυλοειδους
CY1122987T1 (el) Αντισωματα εναντι αμυλοειδους βητα
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
MX2019012445A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EA201100694A1 (ru) Антитело к cd38 человека и его применение
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201692127A1 (ru) Антитела, связывающиеся с человеческим dec-205
CY1114913T1 (el) ΧΡΗΣΗ ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΤΙ-β-ΑΜΥΛΟΕΙΔΟΥΣ ΣΕ ΟΦΘΑΛΜΙΚΕΣ ΑΣΘΕΝΕΙΕΣ
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
WO2010012004A3 (en) Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
CY1120803T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
EA201492162A1 (ru) Антитела к трансглютаминазе 2
DK1786442T3 (da) Behandling af neurodegenerative sygdomme under anvendelse af DEGS-inhibitorer
CY1114604T1 (el) Ανθρωποποιημενο αντισωμα εναντιον αμυλοειδους βητα
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение

Legal Events

Date Code Title Description
FC Refusal